Janssen gains FDA nod for HCV protease inhibitor Olysio

The FDA gave Johnson & Johnson subsidiary Janssen Therapeutics approval on 22 November to market Olysio (simeprevir) as a treatment for chronic hepatitis C virus (HCV) as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin.